These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

111 related articles for article (PubMed ID: 2569263)

  • 1. Urapidil, a multiple-action alpha-blocking drug.
    Prichard BN; Tomlinson B; Renondin JC
    Am J Cardiol; 1989 Aug; 64(7):11D-15D. PubMed ID: 2569263
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical pharmacology of urapidil.
    Prichard BN; Renondin JC; Tomlinson B
    J Hypertens Suppl; 1988 Dec; 6(2):S13-9. PubMed ID: 2906695
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Suppression of reflex tachycardia by central administration of the alpha-1 adrenoceptor antagonists urapidil and prazosin in anesthetized dogs.
    Shebuski RJ; Zimmerman BG
    J Pharmacol Exp Ther; 1985 Aug; 234(2):456-62. PubMed ID: 2862276
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The effect of urapidil on responses to phenylephrine, angiotensin and isoprenaline in man.
    Tomlinson B; Renondin JC; Graham BR; Prichard BN
    Eur J Clin Pharmacol; 1991; 41(1):1-3. PubMed ID: 1685992
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Alpha adrenergic blocking activity of urapidil in man.
    Jamieson MJ; Shepherd AM; Jackson SH; Patel SS; Flanagan PH; Galbraith H
    Res Commun Chem Pathol Pharmacol; 1988 Nov; 62(2):173-85. PubMed ID: 2908008
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Experimental studies on the neurocardiovascular effects of urapidil.
    Gillis RA; Kellar KJ; Quest JA; Namath IJ; Martino-Barrows A; Hill K; Gatti PJ; Dretchen K
    Drugs; 1988; 35 Suppl 6():20-33. PubMed ID: 2900129
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Biotransformation of urapidil: metabolites in serum and urine and their biological activity in vitro and in vivo.
    Zech K; Eltze M; Kilian U; Sanders KH; Kolassa N
    Arch Int Pharmacodyn Ther; 1984 Dec; 272(2):180-96. PubMed ID: 6098228
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Cardiovascular effects of urapidil].
    Bousquet P; Decker N; Feldman J; Schwartz J
    J Pharmacol; 1983; 14(4):465-72. PubMed ID: 6672466
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Analysis of adrenoceptor blockade and hypotension elicited by urapidil and prazosin in conscious rat.
    Goering J; Zimmerman BG
    J Pharmacol Exp Ther; 1986 May; 237(2):553-7. PubMed ID: 2871176
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Involvement of brain 5-HT1A receptors in the hypotensive response to urapidil.
    Kolassa N; Beller KD; Sanders KH
    Am J Cardiol; 1989 Aug; 64(7):7D-10D. PubMed ID: 2569265
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacologic profile of urapidil.
    van Zwieten PA
    Am J Cardiol; 1989 Aug; 64(7):1D-6D. PubMed ID: 2569262
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The role of serotonin-1A receptor activation and alpha-1 adrenoceptor blockade in the hypotensive effect of 5-methyl-urapidil.
    Mandal AK; Kellar KJ; Gillis RA
    J Pharmacol Exp Ther; 1991 May; 257(2):861-9. PubMed ID: 1674536
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical pharmacokinetics of urapidil.
    Kirsten R; Nelson K; Steinijans VW; Zech K; Haerlin R
    Clin Pharmacokinet; 1988 Mar; 14(3):129-40. PubMed ID: 3286082
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Central and peripheral hypotensive activity of urapidil and its M1 and M2 metabolites in the cat.
    Boss H; Boer R; Beller KD; Sanders KH
    Drugs; 1990; 40 Suppl 4():34-7. PubMed ID: 1982652
    [No Abstract]   [Full Text] [Related]  

  • 15. Interaction of urapidil with brain serotonin-1A receptors increases the blood pressure reduction due to peripheral alpha-adrenoceptor inhibition.
    Sanders KH; Beller KD; Bischler P; Kolassa N
    J Hypertens Suppl; 1988 Dec; 6(2):S65-8. PubMed ID: 2906703
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Influence of food intake on the bioavailability of urapidil in healthy volunteers.
    Kirsten R; Nelson K; Molz KH; Gielsdorf W; Haerlin R
    Int J Clin Pharmacol Ther Toxicol; 1989 Jun; 27(6):298-301. PubMed ID: 2737799
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Urapidil permeates the intact blood-brain barrier.
    Castor G; Schmidt U
    Intensive Care Med; 1994; 20(4):278-81. PubMed ID: 7519201
    [TBL] [Abstract][Full Text] [Related]  

  • 18. New alpha 1-adrenergic receptor antagonists for the treatment of hypertension: role of vascular alpha receptors in the control of peripheral resistance.
    Cubeddu LX
    Am Heart J; 1988 Jul; 116(1 Pt 1):133-62. PubMed ID: 2899387
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Involvement of 5-HT1A receptors in blood pressure reduction by 8-OH-DPAT and urapidil in cats.
    Sanders KH; Beller KD; Kolassa N
    J Cardiovasc Pharmacol; 1990; 15 Suppl 7():S86-93. PubMed ID: 1702492
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Importance of central nervous system serotonin-1A receptors for mediating the hypotensive effect of urapidil.
    Mandal AK; Kellar KJ; Friedman E; Pineo SV; Hamosh P; Gillis RA
    J Pharmacol Exp Ther; 1989 Nov; 251(2):563-70. PubMed ID: 2530339
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.